EW - Edwards Lifesciences Corporation
| Previous Close | 159.11 |
| Open | 163.00 |
| Bid | 0.00 x 800 |
| Ask | 200.00 x 900 |
| Day's Range | 162.81 - 168.53 |
| 52 Week Range | 121.40 - 175.00 |
| Volume | 2,305,443 |
| Avg. Volume | 1,528,798 |
| Market Cap | 35.206B |
| Beta (3Y Monthly) | 0.82 |
| PE Ratio (TTM) | 50.68 |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
- Markit•2 days ago
See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
# Edwards Lifesciences Corp ### NYSE:EW View full report here! ## Summary * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Neutral ETF activity is neutral. The net inflows of $7.74 billion over the last one-month into ETFs that hold EW are not among the highest of the last year and have been slowing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- The Wall Street Journal•3 days ago
[$$] Stocks to Watch: Goldman Sachs, Bank of America, Ford, Sears, United Continental, Fiserv, Snap and Facebook
Goldman Sachs, Bank of America, Ford, Sears, United Continental, Fiserv, Snap and Facebook are among Wednesday’s stocks to watch.
- Associated Press•4 days ago
Netflix, UnitedHealth and Edwards climb; Wells Fargo dips
Stocks that moved substantially or traded heavily Tuesday: Netflix Inc., up $21.70 to $354.64 The video streaming company said it will raise prices for its U.S. subscribers. Microsoft Corp., up $2.96 to ...
Motley Fool•4 days agoWhy Netflix, First Republic Bank, and Edwards Lifesciences Jumped Today
Investors liked the streaming-video giant's latest move.
- Investor's Business Daily•4 days ago
Why An IBD 50 Stock And Its Close Rival Are Nearing Breakouts
Edwards Lifesciences and Boston Scientific stocks hit one-month highs Tuesday after the duo settled a patent battle related to transcatheter aortic heart-valve replacements.
- Investor's Business Daily•4 days ago
Indexes Close Higher As FANG Stocks Help Nasdaq Outperform
The stock market closed higher Tuesday after earnings reports and gains for the FANG stocks underscored the day's trading.
- TheStreet.com•4 days ago
Edwards Lifesciences' Stock Jumps on Patent Dispute Settlement
surged nearly 8% on Tuesday after the company agreed to pay rival Boston Scientific Corp. $180 million to settle long-standing patent disputes over heart valve replacement devices. At midday, Edwards Lifesciences' stock rose 8.4% to $162.09 at the close of trading on the New York Stock Exchange.
- American City Business Journals•4 days ago
Boston Scientific settles global heart valve legal battles for $180M
The tools Boston Scientific and Edwards Lifesciences have battled over are used during a relatively new, multibillion-dollar cardiac treatment called transcatheter aortic valve replacement (TAVR).
- Market Realist•4 days ago
Boston Scientific and Edward Lifesciences Settle Patent Dispute
Boston Scientific and Edward Lifesciences Settle Patent DisputeThe stock performance of BSXToday, Boston Scientific (BSX) is trading at $36.76, which is ~4.11% growth from yesterday’s closing price of $35.31. Boston Scientific stock closed at
- Investor's Business Daily•4 days ago
Tech Stocks Advance With These 2 Dow Jones Stocks Mixed On Earnings
The tech-heavy Nasdaq composite led the way early Tuesday. Dow Jones stocks JPMorgan and UnitedHealth reported earnings results.
- Reuters•4 days ago
Edward Lifesciences pays Boston Scientific $180 mln to end patent row
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers. Boston Scientific and Edwards Lifesciences have been embroiled in a number of legal cases for several years involving heart valve replacement systems, including transcatheter aortic valves, in the United States and Europe. All pending cases or appeals in courts and patent offices will be dismissed, the companies said in a joint statement on Tuesday.
- Reuters•4 days ago
Edward Lifesciences settles patent disputes with Boston Scientific
Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in ...
- Markit•10 days ago
See what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
# Edwards Lifesciences Corp ### NYSE:EW View full report here! ## Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low ## Bearish sentiment Short interest | Positive Short interest is low for EW with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. ## Money flow ETF/Index ownership | Positive ETF activity is positive. Over the last month, growth of ETFs holding EW is favorable, with net inflows of $16.78 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. ## Economic sentiment PMI by IHS Markit | Neutral According to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, but is easing. ## Credit worthiness Credit default swap CDS data is not available for this security. Please send all inquiries related to the report to score@ihsmarkit.com. Charts and report PDFs will only be available for 30 days after publishing. This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Kiplinger•11 days ago
The 9 Best Stocks of America’s Last Bear Market
It's official. The Nasdaq Composite has waded all the way into bear-market territory, now down 20% from its late-September peak. The Dow Jones Industrial Average and the Standard & Poor's 500-stock index aren't far behind. Whether the fourth-quarter selloff is merited doesn't entirely matter. If the crowd believes the rout suffered over the course of the past three months is the shape of things to come, stocks will lose more ground as investors create the very bear market they fear. It's a self-fulfilling prophecy. But here at the precipice of seeing the market's condition shift from bad to worse, remember: Not all stocks have to lose ground, even if the tide is going out. One only has to look at the nine big stocks that managed to gain ground between October 2007 and March 2009 - America's last bear market - to appreciate that some companies have staying power even in rough environments. Here are nine S&P; 500 stocks that actually gained in the face of the 2007-09 bear market. Notice in all nine cases, there was something unique about these organizations that shielded them from the full impact of economic woe. And in some cases, they still look properly positioned to fight off another bear attack. ### SEE ALSO: 19 Best Stocks to Buy for 2019 (And 5 to Sell)
- Zacks•11 days ago
Can Edwards Lifesciences (EW) Keep the Earnings Surprise Streak Alive?
Edwards Lifesciences (EW) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
- Investopedia•12 days ago
Top 5 Health Care Stocks of 2018 by Performance
The healthcare sector performed well in 2018, driven by positive growth in sub-segments such as medical devices, health insurance, hospitals, nursing homes, and pharmaceuticals, which offset losses in biomedical and genetics, home healthcare, medical, and dental supplies. Moving ahead into 2019, as the decade-long expansion faces a period of heightened volatility and risk, the health care sector should benefit from a shift towards more defensive sectors. In a recent sector roundup from Charles Schwab, the firm rated health care at "outperform," citing the group’s strong balance sheets, attractive dividend yields, and improved cost structure.
- Investor's Business Daily•22 days ago
Will A New Approval Help This Medical Stock Approach A Breakout?
Edwards Lifesciences gained approval for a new transcatheter heart-valve replacement, or TAVR, system Friday — helping its stock to stay within a consolidation.
- Zacks•22 days ago
Should John Hancock Multifactor Mid Cap ETF (JHMM) Be on Your Investing Radar?
Style Box ETF report for JHMM
Market Realist•23 days agoDo Analysts See Any Upside for Abiomed Stock?
In this year’s second quarter, Abiomed’s (ABMD) net investment income rose YoY (year-over-year) to $1.67 million from $781,000. Abiomed received an income tax benefit of $1.71 million during the second quarter. In comparison, it received an income tax benefit of $7.98 million in the previous year’s period.
Market Realist•23 days agoExamining Abiomed’s Gross Margin Trend
In the second quarter of 2018, Abiomed’s (ABMD) cost of revenue rose YoY (year-over-year) to $29.85 million from $21.63 million due to higher production volumes and higher costs in support of higher demand for its Impella devices. Its gross margin contracted YoY to 83.58% from 83.72%. Expected trends
Market Realist•23 days agoExploring Abiomed’s Latest Performance Trends
Abiomed (ABMD) provides mechanical circulatory support devices and care for heart failure patients. Its products enable the heart to rest, heal, and recover by improving blood flow and assisting the heart’s pumping function. They are used in the cardiac catheterization lab, by interventional cardiologists, and in heart surgery.
- Investor's Business Daily•23 days ago
Robots, DNA And Implantable Devices — Why 2019 Isn't Your Dad's Medtech
Innovation will continue in medical technology with a deeper influence from robotics, DNA sequencing and implantable devices, analysts say. Medtech stocks are expected to be strong in 2019.
- Simply Wall St.•29 days ago
When Should You Buy Edwards Lifesciences Corporation (NYSE:EW)?
Let's talk about the popular Edwards Lifesciences Corporation (NYSE:EW). The company's shares received a lot of attention from a substantial price movement on the NYSE over the last few months, Read More...
- Zacks•last month
Will Walgreens (WBA) Q1 Earnings Gain From Overall Strength?
Several planned developments, early benefits from new pharmacy contracts as well as increased volumes are consistently driving growth within Walgreens Boots' (WBA) Retail Pharmacy USA division.
Markit•last monthSee what the IHS Markit Score report has to say about Edwards Lifesciences Corp.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
